Plasma Levels of Citalopram in Depressed Patients with Hepatitis C

Psychosomatics

Volumn 45, Issue 1, 2004, Pages 29-33

  Gleason, Ondria C ^a   Yates, William R ^b   Philipsen, Michelle A ^b   Isbell, M Daniel ^b   Pollock, Bruce G ^b  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; INTERFERON;

ADULT; AGED; ANORGASMIA; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; DEPRESSION; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG BLOOD LEVEL; DRUG TOLERABILITY; EJACULATION DISORDER; FEMALE; HEADACHE; HEPATITIS C; HUMAN; HYPERHIDROSIS; INSOMNIA; MALE; NAUSEA; SEXUAL DYSFUNCTION; SOMNOLENCE; XEROSTOMIA; YAWNING;

EID: 0347724140     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.45.1.29     Document Type: Article

References (19)

1. Alter MJ: Epidemiology of hepatitis C. Hepatology 1997; 26(3, suppl 1):62S-65S
2. Kraus MR, Schäfer A, Csef H, Scheurlen M, Faller H: Emotional state, coping styles, and somatic variables in patients with chronic hepatitis C. Psychosomatics 2000; 41:377-384
3. Dwight MM, Kowdley KV, Russo JE, Ciechanowski PS, Larson AM, Katon WJ: Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res 2000; 49:311-317
4. Lee DH, Jamal H, Regenstein FG, Perrillo RP: Morbidity of chronic hepatitis C as seen in a tertiary care medical center. Dig Dis Sci 1997; 42:186-191
5. Yovtcheva SP, Rifai MA, Moles JK, Van der Linden BJ: Psychiatric comorbidity among hepatitis C-positive patients. Psychosomatics 2001; 45:411-415
6. Regier DA, Kaelber CT, Rae DS, Farmer ME, Knauper B, Kessler RC, Norquist GS: Limitations of diagnostic criteria and assessment instruments for mental disorders: implications for research and policy. Arch Gen Psychiatry 1998; 55:109-115
7. Weiss K: Safety profile of interferon-alpha therapy. Semin Oncol 1998; 25(Feb suppl 1):9-13
8. McDonald EM, Mann AH, Thomas HC: Interferons as mediators of psychiatric morbidity. Lancet 1987; 2:1175-1178
9. Merimsky O, Chaitchik S: Neurotoxicity of interferon-alpha. Anticancer Drugs 1992; 3:567-570
10. Gleason OC, Yates WR, Isbell MD, Philipsen MA: An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry 2002; 63:194-198
11. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders (SCID), Clinician Version. Washington, DC, American Psychiatric Press, 1996
12. Folstein MF, Folstein SE, McHugh PR: "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198
13. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 180-192
14. Ware JE Jr, Sherboume CD: The MOS 36-Item Short-Form Health Survey (SF-36), I: conceptual framework and item selection. Med Care 1992; 30:473-483
15. Derogatis LR, Lazarus L: SCL-90-R, Brief Symptom Inventory, and matching clinical rating scales, in The Use of Psychological Testing for Treatment Planning and Outcome Assessment. Edited by Maruish M. New York, Lawrence Erlbaum Associates, 1994, pp 217-248
16. Guy W, Bonato R (eds): Manual for the ECDEU Assessment Battery, 2nd ed. Chevy Chase, Md, National Institute of Mental Health, 1970, pp 12-1-12-6
17. Pollock BG, Mulsant BH, Sweet R, Burgio LD, Kirshner MA, Shuster K, Rosen J: An open pilot study of citalopram for behavioral disturbances of dementia: plasma levels and real-time observations. Am J Geriatr Psychiatry 1997; 5:70-78
18. Montgomery SA, Rasmussen JGC, Tanghoj P: A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993; 8:181-188
19. Baumann P, Larsen F: The pharmacokinetics of citalopram. Reviews in Contemporary Pharmacotherapy 1995; 6:287-295